Subgroup analyses indicated that the mPFS and mOS had no significant difference across all subgroups, including the location of primary tumor, visceral metastases, previous chemotherapy, previous treatment of PD-1/PD-L1 inhibitors, and HER2 status (Appendix Figs A3A and A3B). This evidence concerns the gene CD274 and neoplasm.